ArticleMolecular biology reports2026
ASAP1 as a novel dual-level biomarker for tuberculosis: integrated genetic and proteomic evidence for early detection and disease monitoring.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a major global health challenge, with limitations in current diagnostics prompting interest in host-derived biomarkers. This study evaluated the role of ASAP1, a regulator of actin cytoskeleton remodeling and dendritic cell migration, as a genetic and molecular biomarker for TB. A case–control cohort comprising 164 TB patients and 85 healthy controls was analyzed for two intronic ASAP1 single-nucleotide polymorphisms (SNPs), rs4733781 (A > C) and rs10956514 (G > A), along with peripheral blood mRNA expression and serum protein levels. METHODOLOGY AND
resultsGenotypic analysis revealed no significant differences in allele frequencies between groups; however, rs4733781 was significantly associated with TB under the dominant genetic model (OR = 1.95, 95% CI = 1.08–3.53, p = 0.04). Haplotype analysis identified a C–G–A–G configuration as more frequent in TB cases (OR = 15.78, p = 0.02). Expression quantitative trait loci (eQTL) data confirmed genotype-dependent variation in ASAP1 transcript levels. In this cohort, qPCR demonstrated markedly elevated ASAP1 mRNA expression in TB patients versus controls (mean 9.39-fold vs 1.26-fold; p < 0.001; AUC = 0.84), with a threshold of 5.134-fold yielding 75.0% sensitivity and 100% specificity. ELISA measurements showed higher serum ASAP1 protein levels in TB patients without rifampicin resistance compared to controls (median 137.61 vs. 65.71 ng/mL; p = 0.002; AUC = 0.64). The “either-positive” combination of mRNA and protein thresholds improved sensitivity to 92.1% while maintaining 85.5% specificity, whereas the “both-positive” rule achieved perfect specificity but lower sensitivity (51.3%).
conclusionProtein–protein interaction analysis linked ASAP1 to immune regulatory and cytoskeletal proteins, supporting its functional relevance in TB pathogenesis. These findings suggest that ASAP1, at both transcript and protein levels, is a promising candidate for inclusion in biomarker panels, with potential applications in confirmatory diagnosis and high-yield screening strategies. Further validation in larger, diverse, and longitudinal cohorts is warranted.
Indexed as
Identifiers
41627576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.